An Arizona research team found molecular targets in 98% of 66 patients studied, and 18 people had longer progression-free survival times with targeted therapy compared to previous generalized therapies they had tried. A separate Italian study found genetic mutations in patients with advanced colorectal cancer that could indicate their tumors wouldn't respond to specific drugs.

Full Story:

Related Summaries